Trimodal Therapy for Histologically Proven N2/3 Non–Small Cell Lung Cancer: Mid-Term Results and Indicators for Survival

Multimodality Treatment With Surgery for Locally Advanced Non–Small-Cell Lung Cancer With N2 Disease: A Review Article

“…There are many retrospective studies reporting the treatment outcomes of preoperative chemoradiotherapy followed by subsequent resection in patients with stage III disease, [33][34][35][36][37][38][39][40][41][42][43] and several prospective studies have been conducted to evaluate preoperative treatment, including concurrent chemoradiotherapy, followed by surgery in those with stage III NSCLC. [21][22][23][24][44][45][46][47][48][49][50] However, the results are inconsistent, and conclusive evidence has yet to be obtained.…”

Impact of neo-adjuvant radiochemotherapy on bronchial tissue viability☆

“…It was not the objective of the conducted study to analyse the general clinical benefit and the long-term results of neo- [15]. In this study, the objective was to elucidate the impact of neo-adjuvant RCTX on bronchial tissue homeostasis contributing to postoperative BPF.…”

“…This afforded a congruent treatment regime without modification of the multimodal approach combining polychemotherapy, high-dosage radiotherapy and standardised surgery. The presence of 32% (14 out of 44) patients following neo-adjuvant RCTX represents our clinical practice, where one-third of our NSCLC patients have advanced disease (UICC stage IIIa and IIIb) and therefore receive neo-adjuvant therapy [15]. Since only patients with sufficient functional capabilities following RCTX are offered surgery, our inclusion policy results in a bias favouring younger patients in the RCTX group.…”

“…Ten years ago, an aggressive neo-adjuvant trimodality protocol including seven cycles of polychemotherapy and an accelerated hyperfractionated radiotherapy with a cumulative dose of 45 Gy (representing 50-90 Gy standard fractionation) was implemented at the clinic Schillerhoehe, whose first long-term clinical results have been published recently [15]. To identify and quantify its specific impact on bronchial tissue viability setting the basis for unhindered bronchial stump healing, this cytological study was conducted and its findings were matched with the patients' clinical course.…”

“…A detailed description of our diagnostic work-up and our surgical techniques has been published recently [15]. Briefly, oncologic and functional staging including cervical mediastinoscopy were performed according to the European Society of Thoracic Surgeons (ESTS) guidelines [16].…”